Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMINO7Z)

Drug Name
Perhexiline Drug Info
Synonyms
Perhexilene; Perhexilina; Perhexilinum; Perhexilline; Perhexilina [INN-Spanish]; Perhexiline (INN); Perhexiline [INN:BAN]; Perhexilinum [INN-Latin]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [1]
Therapeutic Class
Vasodilator Agents
Cross-matching ID
PubChem CID
4746
ChEBI ID
CHEBI:35553
CAS Number
CAS 39648-47-0
TTD Drug ID
DMINO7Z
INTEDE Drug ID
DR1260

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Carnitine O-palmitoyltransferase I (CPT1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Levacecarnine hci DMJBOCR Cognitive impairment 6D71 Approved [6]
SDZ-CPI-975 DM70MJQ Diabetic complication 5A2Y Discontinued in Phase 1 [7]
Etomoxir DM3BHN1 Heart failure BD10-BD13 Terminated [8]
DB-200 DMTXPSB Psoriasis vulgaris EA90 Terminated [9]
C75 DMHGX1N Obesity 5B81 Investigative [10]
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [11]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [12]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [13]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [14]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [15]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [16]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [17]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [18]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [12]
Verapamil DMA7PEW Angina pectoris BA40 Approved [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [20]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [21]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [22]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [15]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [19]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [23]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [24]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [25]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [26]
Propranolol DM79NTF Angina pectoris BA40 Approved [27]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [38]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [39]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [40]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [41]
Oxatomide DM1F42Z Hay fever CA08.00 Approved [42]
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [43]
Capsaicin DMGMF6V Back pain ME84.Z Approved [44]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [45]
Quinidine DMLPICK N. A. N. A. Approved [46]
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [47]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [28]
Verapamil DMA7PEW Angina pectoris BA40 Approved [29]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [30]
Estrone DM5T6US Acne vulgaris ED80 Approved [31]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [32]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [33]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [34]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [35]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [36]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alpha-1-antichymotrypsin (SERPINA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [48]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [49]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [50]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [51]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [51]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Serine protease hepsin (HPN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Selenium DM25CGV N. A. N. A. Approved [52]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [4]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [3]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [54]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [55]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Fatty acid-binding protein, liver (FABP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [56]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [49]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Methotrexate DM2TEOL Anterior urethra cancer Approved [57]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [58]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-deoxyglucose DMIAHVU Solid tumour/cancer 2A00-2F9Z Approved [59]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [60]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [49]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Methotrexate DM2TEOL Anterior urethra cancer Approved [61]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lanosterol synthase (LSS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [63]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [64]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [65]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [4]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transgelin (TAGLN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [66]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [49]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Methotrexate DM2TEOL Anterior urethra cancer Approved [67]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [68]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Acid ceramidase (ASAH1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [69]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [4]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [70]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [4]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [71]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcipotriol DM03CP7 Psoriasis EA90 Approved [72]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [73]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [74]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [63]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [4]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [75]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lysophospholipase D GDPD3 (GDPD3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [49]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [4]
Fluoxetine DM3PD2C Bipolar depression Approved [4]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [3]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [76]
Testosterone DM7HUNW Hot flushes GA30 Approved [77]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [77]
Haloperidol DM96SE0 Delirium Approved [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Fibronectin type III domain-containing protein 4 (FNDC4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [4]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [3]
Haloperidol DM96SE0 Delirium Approved [4]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [55]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [78]
Clozapine DMFC71L Schizophrenia 6A20 Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein DEPP1 (DEPP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [4]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [79]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [80]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [4]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nuclear protein 1 (NUPR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [81]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [4]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [49]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [82]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Asparagine synthetase (ASNS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [83]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [84]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [85]
Methotrexate DM2TEOL Anterior urethra cancer Approved [86]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [4]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [87]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [88]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Inhibin beta E chain (INHBE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [3]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [49]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [3]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [65]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [4]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [3]
Panobinostat DM58WKG Chronic graft versus host disease Approved [89]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By AP-1 complex subunit sigma-1A (AP1S1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [90]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [3]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Fluoxetine DM3PD2C Bipolar depression Approved [3]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [4]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [91]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [55]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [92]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [93]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transmembrane protease serine 2 (TMPRSS2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [94]
Diazepam DM08E9O Alcohol withdrawal Approved [94]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [56]
Selenium DM25CGV N. A. N. A. Approved [52]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [94]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [94]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [94]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [94]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [94]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [94]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Paclitaxel DMLB81S Breast carcinoma Approved [95]
Verapamil DMA7PEW Angina pectoris BA40 Approved [96]
Methysergide DM1EF73 Migraine 8A80 Approved [97]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [63]
Methotrexate DM2TEOL Anterior urethra cancer Approved [61]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [97]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [64]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [58]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [98]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [99]
Quinidine DMLPICK N. A. N. A. Approved [100]
Verapamil DMA7PEW Angina pectoris BA40 Approved [101]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [102]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [102]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [103]
Propranolol DM79NTF Angina pectoris BA40 Approved [104]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [105]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [106]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [102]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carnitine O-palmitoyltransferase I (CPT1B) TTDL0NY CPT1B_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [2]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [2]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Gene/Protein Processing [3]
Alpha-1-antichymotrypsin (SERPINA3) OT9BP2S0 AACT_HUMAN Gene/Protein Processing [3]
AP-1 complex subunit sigma-1A (AP1S1) OTQ2H8DN AP1S1_HUMAN Gene/Protein Processing [4]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Drug Response [5]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Gene/Protein Processing [3]
Fibronectin type III domain-containing protein 4 (FNDC4) OTOQK0WK FNDC4_HUMAN Gene/Protein Processing [3]
Inhibin beta E chain (INHBE) OTOI2NYG INHBE_HUMAN Gene/Protein Processing [4]
Lanosterol synthase (LSS) OT9W2SFH LSS_HUMAN Gene/Protein Processing [3]
Lysophospholipase D GDPD3 (GDPD3) OTOHM9QM GDPD3_HUMAN Gene/Protein Processing [3]

References

1 Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97.
2 CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
3 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
4 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
5 Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury. Arch Toxicol. 2018 Jan;92(1):383-399. doi: 10.1007/s00204-017-2036-4. Epub 2017 Jul 31.
6 Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74.
7 Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol. 1998 Feb;274(2 Pt 2):R524-8.
8 Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43.
9 Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy. Cardioscience. 1994 Sep;5(3):193-7.
10 C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
21 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
22 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
23 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
24 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
25 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
26 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
27 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
28 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
29 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
30 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
31 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
32 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
33 Drugs that may have potential CYP2B6 interactions.
34 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
35 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
36 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
37 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
38 Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
39 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
40 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
41 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
42 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
43 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
44 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
45 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
46 Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
47 Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
48 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
49 In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
50 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
51 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
52 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
53 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
54 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
55 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
56 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
57 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
58 Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
59 Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J. 1993 Mar 15;290 ( Pt 3)(Pt 3):701-6. doi: 10.1042/bj2900701.
60 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
61 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
62 Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
63 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
64 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
65 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
66 Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
67 Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
68 Differentiation of human embryonic stem cells into smooth muscle cells in adherent monolayer culture. Biochem Biophys Res Commun. 2006 Dec 15;351(2):321-7. doi: 10.1016/j.bbrc.2006.09.171. Epub 2006 Oct 17.
69 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
70 MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
71 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
72 Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
73 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
74 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
75 Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
76 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
77 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
78 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
79 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
80 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
81 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
82 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
83 Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
84 Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
85 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
86 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
87 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
88 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
89 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
90 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
91 An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
92 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
93 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
94 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
95 [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
96 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
97 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
98 Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
99 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
100 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
101 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
102 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
103 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
104 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
105 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
106 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.